TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · IEX Real-Time Price · USD
0.969
-0.051 (-5.01%)
At close: Jun 21, 2024, 4:00 PM
0.980
+0.011 (1.15%)
After-hours: Jun 21, 2024, 7:50 PM EDT

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019
Selling, General & Admin
7.158.43.40.440.23
Research & Development
12.2610.232.750.280.23
Operating Expenses
19.4218.636.150.730.46
Operating Income
-19.42-18.63-6.15-0.73-0.46
Interest Expense / Income
0.060.030.10.390.16
Other Expense / Income
-0.93-1.10.61.22-0.01
Pretax Income
-18.55-17.56-6.84-2.34-0.61
Net Income
-18.55-17.56-6.84-2.34-0.61
Shares Outstanding (Basic)
00000
Shares Outstanding (Diluted)
00000
Shares Change
1003.48%54.03%81.74%--
EPS (Basic)
-103.61-1082.79-648.00-408.00-104.00
EPS (Diluted)
-103.61-1082.79-648.00-408.00-104.00
Free Cash Flow
-18.11-15.86-5.52-0.49-0.51
Free Cash Flow Per Share
-101.17-977.90-523.98-85.06-87.75
EBITDA
-17.97-17.43-6.71-1.95-0.45
Depreciation & Amortization
0.520.10.0400
EBIT
-18.49-17.53-6.75-1.95-0.45
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).